CutisPharma Acquires Silvergate Pharmaceuticals and Rebrands as Azurity Pharmaceuticals
June 12, 2019
CutisPharma, majority-backed by NovaQuest Private Equity (now QHP Capital), has acquired Silvergate Pharmaceuticals and the combined company will be rebranded as Azurity Pharmaceuticals. The transaction consolidates complementary specialty pharmaceutical portfolios and capabilities—combining CutisPharma’s recently launched products with Silvergate’s SG-05 pipeline submission—and is supported by debt financing arranged by Goldman Sachs Specialty Lending Group.
- Buyers
- CutisPharma, Inc., NovaQuest Private Equity (QHP Capital)
- Targets
- Silvergate Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Colorado, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
September 24, 2021
Pharmaceuticals
Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.
-
Azurity Pharmaceuticals Acquires Slayback Pharma
September 27, 2023
Pharmaceuticals
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
-
Azurity Pharmaceuticals Acquires Covis Pharma
March 14, 2025
Pharmaceuticals
Azurity Pharmaceuticals has completed its acquisition of Covis Group S.à r.l. (Covis Pharma) from existing investors, making Covis a wholly owned subsidiary of Azurity. The deal expands Azurity's therapeutic portfolio across multiple complex dosage forms and broadens its global footprint, with the combined company serving 50+ countries and employing more than 800 colleagues.
-
Navitus Health Solutions Acquires EpiphanyRx; Lumicera Purchases Quality Drug Clinical Care
July 19, 2021
Healthcare Services
Navitus Health Solutions has acquired EpiphanyRx to broaden its PBM capabilities and mid-market employer reach. Its specialty pharmacy arm, Lumicera Health Services, also acquired Quality Drug Clinical Care in Irvine, California to expand Lumicera's specialty pharmacy footprint and HIV clinical services in the western United States.
-
AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction
December 31, 2022
Healthcare Services
AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.
-
Apotex Acquires Searchlight Pharma
April 2, 2024
Pharmaceuticals
Apotex Inc. has completed the acquisition of Montreal-based Searchlight Pharma Inc., integrating Searchlight as Apotex's Specialty Pharma Division to expand its branded and specialty pharmaceutical capabilities. The deal adds Searchlight's portfolio of more than 60 products across women's health, dermatology, allergy, pain management and hospital specialty markets, and strengthens Apotex's commercial footprint in Quebec and across the Americas.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.